304 related articles for article (PubMed ID: 32456352)
1. Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma.
Argentiero A; Solimando AG; Krebs M; Leone P; Susca N; Brunetti O; Racanelli V; Vacca A; Silvestris N
J Clin Med; 2020 May; 9(5):. PubMed ID: 32456352
[TBL] [Abstract][Full Text] [Related]
2. Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers.
Signoretti S; Flaifel A; Chen YB; Reuter VE
J Clin Oncol; 2018 Oct; 36(36):JCO2018792259. PubMed ID: 30372384
[TBL] [Abstract][Full Text] [Related]
3. Importance of Multiparametric Evaluation of Immune-Related T-Cell Markers in Renal-Cell Carcinoma.
Kawashima A; Uemura M; Nonomura N
Clin Genitourin Cancer; 2019 Dec; 17(6):e1147-e1152. PubMed ID: 31473121
[TBL] [Abstract][Full Text] [Related]
4. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
5. The Identification of Immunological Biomarkers in Kidney Cancers.
Lopez-Beltran A; Henriques V; Cimadamore A; Santoni M; Cheng L; Gevaert T; Blanca A; Massari F; Scarpelli M; Montironi R
Front Oncol; 2018; 8():456. PubMed ID: 30450335
[TBL] [Abstract][Full Text] [Related]
6. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.
Godwin JL; Zibelman M; Plimack ER; Geynisman DM
Discov Med; 2014 Dec; 18(101):341-50. PubMed ID: 25549705
[TBL] [Abstract][Full Text] [Related]
8. Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation.
Vlachostergios PJ
J Kidney Cancer VHL; 2020; 7(1):7-11. PubMed ID: 32983840
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
10. Targeting angiogenesis in metastatic renal cell carcinoma.
Canino C; Perrone L; Bosco E; Saltalamacchia G; Mosca A; Rizzo M; Porta C
Expert Rev Anticancer Ther; 2019 Mar; 19(3):245-257. PubMed ID: 30678509
[TBL] [Abstract][Full Text] [Related]
11. Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor.
Mollica V; Di Nunno V; Gatto L; Santoni M; Scarpelli M; Cimadamore A; Lopez-Beltran A; Cheng L; Battelli N; Montironi R; Massari F
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31207938
[TBL] [Abstract][Full Text] [Related]
12. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
Liu XD; Hoang A; Zhou L; Kalra S; Yetil A; Sun M; Ding Z; Zhang X; Bai S; German P; Tamboli P; Rao P; Karam JA; Wood C; Matin S; Zurita A; Bex A; Griffioen AW; Gao J; Sharma P; Tannir N; Sircar K; Jonasch E
Cancer Immunol Res; 2015 Sep; 3(9):1017-29. PubMed ID: 26014097
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
Su D; Singer EA; Srinivasan R
Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
[TBL] [Abstract][Full Text] [Related]
14. The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma.
Bilen MA; Carlisle JW; Sonpavde G
Expert Opin Investig Drugs; 2018 Feb; 27(2):163-170. PubMed ID: 29323560
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy.
Heidegger I; Pircher A; Pichler R
Front Oncol; 2019; 9():490. PubMed ID: 31259150
[TBL] [Abstract][Full Text] [Related]
16. Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma.
Zarrabi KK; Lanade O; Geynisman DM
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230530
[TBL] [Abstract][Full Text] [Related]
17. Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios.
Cetin B; Kosar A
Int Urol Nephrol; 2019 Dec; 51(12):2107-2117. PubMed ID: 31468288
[TBL] [Abstract][Full Text] [Related]
18. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
19. The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
Botticelli A; Cirillo A; Scagnoli S; Cerbelli B; Strigari L; Cortellini A; Pizzuti L; Vici P; De Galitiis F; Di Pietro FR; Cerbelli E; Ghidini M; D'Amati G; Della Rocca C; Mezi S; Gelibter A; Giusti R; Cortesi E; Ascierto PA; Nuti M; Marchetti P
Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32353934
[TBL] [Abstract][Full Text] [Related]
20. The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment.
Brighi N; Farolfi A; Conteduca V; Gurioli G; Gargiulo S; Gallà V; Schepisi G; Lolli C; Casadei C; De Giorgi U
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
